These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8021335)

  • 1. Comparison of the pharmacokinetics, pharmacodynamics, and safety of oral (Catapres) and transdermal (M-5041T) clonidine in healthy subjects.
    Fujimura A; Ebihara A; Ohashi K; Shiga T; Kumagai Y; Nakashima H; Kotegawa T
    J Clin Pharmacol; 1994 Mar; 34(3):260-5. PubMed ID: 8021335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of a new transdermal clonidine, M-5041T, in healthy subjects.
    Fujimura A; Ebihara A; Shiga T; Kumagai Y; Ohashi K; Nakashima H; Kotegawa T
    J Clin Pharmacol; 1993 Dec; 33(12):1192-200. PubMed ID: 8126254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of application site of a new transdermal clonidine, M-5041T, on its pharmacokinetics and pharmacodynamics in healthy subjects.
    Ebihara A; Fujimura A; Ohashi K; Shiga T; Kumagai Y; Nakashima H; Kotegawa T
    J Clin Pharmacol; 1993 Dec; 33(12):1188-91. PubMed ID: 8126253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of nitroglycerin and clonidine delivered by the transdermal route.
    Shaw JE
    Am Heart J; 1984 Jul; 108(1):217-23. PubMed ID: 6428208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influences of bathing and hot weather on the pharmacokinetics of a new transdermal clonidine, M-5041T.
    Fujimura A; Sasaki M; Harada K; Kumagai Y; Ohashi K; Ebihara A
    J Clin Pharmacol; 1996 Oct; 36(10):892-6. PubMed ID: 8930775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive effects of a new transdermal delivery system for clonidine (M-5041T) in spontaneously hypertensive rats.
    Ishii R; Naruse T; Tagawa T; Yamahata T; Dote S; Hamada K; Ishida T; Funabiki K; Namba K
    Arch Int Pharmacodyn Ther; 1994; 327(3):294-308. PubMed ID: 7848013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive effects of a new transdermal delivery system for clonidine in genetic and experimental hypertensive rats.
    Ishii R; Tagawa T; Ishida T; Naruse T
    Arzneimittelforschung; 1996 Mar; 46(3):261-8. PubMed ID: 8901146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient acceptance of transdermal clonidine. A retrospective review of 25 patients.
    Chen SW; Vidt DG
    Cleve Clin J Med; 1989; 56(1):21-6. PubMed ID: 2731324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal and oral clonidine.
    Lilja M; Juustila H; Sarna S; Jounela AJ
    Ann Med; 1991 Aug; 23(3):265-9. PubMed ID: 1930916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of transdermally administered clonidine.
    Arndts D; Arndts K
    Eur J Clin Pharmacol; 1984; 26(1):79-85. PubMed ID: 6714294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal clonidine (Catapres-TTS) monotherapy in the management of mild hypertension in general practice.
    Lewis GR
    N Z Med J; 1987 Nov; 100(836):711-3. PubMed ID: 3330602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro/in vivo functionality of Catapres-TTS.
    Enscore DJ; Osborne JL; Shaw JE
    Methods Find Exp Clin Pharmacol; 1989 Mar; 11(3):173-8. PubMed ID: 2657275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo characterization of a newly developed clonidine transdermal patch for treatment of attention deficit hyperactivity disorder in children.
    Ke GM; Wang L; Xue HY; Lu WL; Zhang X; Zhang Q; Guo HY
    Biol Pharm Bull; 2005 Feb; 28(2):305-10. PubMed ID: 15684489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A community-based trial of transdermal antihypertensive therapy with clonidine (Catapres-TTS).
    Kellaway GS; Lubbe WF
    N Z Med J; 1986 Sep; 99(810):711-4. PubMed ID: 3547202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical assessment of a new transdermal delivery system for clonidine (M-5041T).
    Naruse T; Ishida T; Ishii R; Tagawa T
    Fundam Clin Pharmacol; 1996; 10(1):47-55. PubMed ID: 8900500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a newly developed transdermal clonidine delivery system (M-5041T) on EEG sleep-wake cycle in relation to plasma concentration in rabbits.
    Kimura K; Ishihara K; Tagawa T; Sakurai M; Fujii Y; Dote S; Naruse T; Sasa M; Namba K
    Gen Pharmacol; 1996 Jan; 27(1):73-7. PubMed ID: 8742497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal clonidine compared with hydrochlorothiazide as monotherapy in elderly hypertensive males.
    Schmidt GR; Schuna AA; Goodfriend TL
    J Clin Pharmacol; 1989 Feb; 29(2):133-9. PubMed ID: 2715369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transdermal clonidine for hypertensive patients.
    Popli S; Stroka G; Ing TS; Daugirdas JT; Norusis MJ; Hano JE; Gandhi VC
    Clin Ther; 1983; 5(6):624-8. PubMed ID: 6627288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacokinetics of oral versus sublingual clonidine.
    Cunningham FE; Baughman VL; Peters J; Laurito CE
    J Clin Anesth; 1994; 6(5):430-3. PubMed ID: 7986518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of clonidine as transdermal therapeutic system: the international clinical trial experience.
    Lowenthal DT; Saris S; Paran E; Cristal N; Sharif K; Bies C; Fagan T
    Am Heart J; 1986 Oct; 112(4):893-900. PubMed ID: 3532747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.